Revolutionizing cancer immunotherapy: T cell engagers beyond hematologic malignancies toward solid tumors

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• T cell engagers (TCEs) redirect T cells to target cancer cells, showing success in blood cancers.
• TCEs are increasingly explored for solid tumors, with tarlatamab approved for small cell lung cancer (SCLC).
• Limited efficacy in solid tumors is due to immunosuppressive tumor microenvironments (TME), toxicity, and resistance.

Purpose of the Study:

• To review recent advancements in TCE development for solid tumors.
• To discuss strategies for overcoming resistance and improving TCE therapy outcomes.
• To explore next-generation engager platforms and their potential.

Main Methods:

• Literature review of recent advances in TCE development for solid tumors.
• Analysis of molecular design refinements, biomarker strategies, and combination therapies.
• Discussion of emerging next-generation engager platforms.

Main Results:

• Refinements in molecular design enhance TCE specificity and efficacy.
• Biomarker-guided patient selection improves therapeutic targeting.
• Combination strategies and next-generation platforms show potential to overcome resistance.

Conclusions:

• TCEs hold significant potential for treating solid tumors.
• Overcoming TME-mediated immunosuppression and resistance is crucial for clinical success.
• Innovations in TCE design and application promise more effective cancer immunotherapies.